User:Mr. Ibrahem/Tixagevimab/cilgavimab

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Tixagevimab/cilgavimab
Tixagevimab (teal, right) and cilgavimab (purple, left) binding the spike protein RBD. From PDB: 7L7E​.
Combination of
TixagevimabMonoclonal antibody
CilgavimabMonoclonal antibody
Clinical data
Trade namesEvusheld
Other namesAZD7442
AHFS/Drugs.comMonograph
MedlinePlusa621058
License data
Pregnancy
category
Routes of
administration		Intramuscular
Legal status
Legal status

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a medication used to prevent COVID-19 before exposure.[10][11] It may be used in those who weight more than 40 kg or are older than 12 years.[10] It is given by injection into a muscle.[10] Evidence supports benefits for up to six month.[10]

Common side effects are allergic reactions, headaches, tiredness, and pain at the site of injection.[10][11] Other serious side effects may include anaphylaxis and heart problems.[11] Safety in pregnancy is unclear.[11] It is a combination of two monoclonal antibody, tixagevimab and cilgavimab.[10] It works by binding the spike protein of SARS-CoV-2 which prevents it from entering cells.[10]

The combination was approved for medical use in Europe in March and in Canada in April of 2022.[10][12] In the United States it received Emergency Use Authorization in December of 2021.[11] In the United States the government pays about 855 USD per dose.[13] The cost to the individual is generally less than 10 USD.[14]

References[edit]

  1. ^ a b "Evusheld". Therapeutic Goods Administration (TGA). 7 March 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
  2. ^ "Evusheld". Therapeutic Goods Administration (TGA). Archived from the original on 24 March 2022. Retrieved 23 March 2022.
  3. ^ "AusPAR: Tixagevimab and cilgavimab". Therapeutic Goods Administration (TGA). 11 March 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
  4. ^ "Evusheld- azd7442 kit". DailyMed. AstraZeneca. 20 December 2021. Archived from the original on 5 January 2022. Retrieved 20 January 2022.
  5. ^ "Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ O'Shaughnessy A (20 December 2021). "Re: Emergency Use Authorization 104" (PDF). Food and Drug Administration. Letter to AstraZeneca Pharmaceuticals LP | Attention: Stacey Cromer Berman, PhD. Archived from the original on 29 December 2021. Retrieved 18 January 2022.
  7. ^ "FDA authorizes revisions to Evusheld dosing". U.S. Food and Drug Administration (FDA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022.
  8. ^ "Evusheld EPAR". European Medicines Agency (EMA). 22 March 2022. Archived from the original on 16 April 2022. Retrieved 24 April 2022.
  9. ^ "Evusheld". Union Register of medicinal products. 25 March 2022. Archived from the original on 28 March 2022. Retrieved 24 April 2022.
  10. ^ a b c d e f g h i j k "Evusheld". Archived from the original on 16 April 2022. Retrieved 26 April 2022.
  11. ^ a b c d e f "Tixagevimab and Cilgavimab Monograph for Professionals". Drugs.com. Archived from the original on 21 April 2022. Retrieved 26 April 2022.
  12. ^ Canada, Health (14 April 2022). "Health Canada authorizes Evusheld for the prevention of COVID-19 in immune compromised adults and children". www.canada.ca. Archived from the original on 25 April 2022. Retrieved 26 April 2022.
  13. ^ McDade, Aaron (11 February 2022). "Army awards AstraZeneca $855M contract for Evusheld COVID treatment". Newsweek. Archived from the original on 26 April 2022. Retrieved 26 April 2022.
  14. ^ "Evusheld Prices and Evusheld Coupons". GoodRx. Archived from the original on 28 April 2022. Retrieved 26 April 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tixagevimab/cilgavimab&oldid=1160279073"